AstraZeneca plc (LON:AZN)‘s stock had its “buy” rating reaffirmed by stock analysts at Citigroup Inc. in a research report issued on Thursday, July 13th, MarketBeat Ratings reports. They presently have a GBX 6,000 ($78.14) price target on the biopharmaceutical company’s stock. Citigroup Inc.’s price target suggests a potential upside of 31.46% from the stock’s current price.
AZN has been the topic of several other reports. Morgan Stanley restated an “overweight” rating and issued a GBX 5,600 ($72.93) price target on shares of AstraZeneca plc in a research note on Friday, June 23rd. Deutsche Bank AG restated a “buy” rating on shares of AstraZeneca plc in a research note on Monday, May 22nd. J P Morgan Chase & Co restated a “neutral” rating and issued a GBX 4,200 ($54.69) price target on shares of AstraZeneca plc in a research note on Tuesday, March 21st. Beaufort Securities restated a “hold” rating on shares of AstraZeneca plc in a research note on Thursday, March 16th. Finally, Shore Capital restated a “sell” rating on shares of AstraZeneca plc in a research note on Thursday, May 4th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of GBX 4,937.43 ($64.30).
AstraZeneca plc (AZN) opened at 4564.00 on Thursday. AstraZeneca plc has a 12-month low of GBX 3,996.00 and a 12-month high of GBX 5,520.00. The stock’s 50 day moving average is GBX 5,022.16 and its 200-day moving average is GBX 4,861.45. The company’s market capitalization is GBX 57.78 billion.
In other news, insider Nazneen Rahman acquired 39 shares of the stock in a transaction dated Thursday, July 27th. The stock was bought at an average price of GBX 4,370 ($56.91) per share, with a total value of £1,704.30 ($2,219.43).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with our FREE daily email newsletter.